Almirall and Absci (ABSI) announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases Nov 14, 2023 06:54AM
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases Nov 14, 2023 02:16AM
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab Feb 12, 2019 02:00AM
Alpha MOS Successfully Completes Final Sensory Quality Assurance System Testing in Coca-Cola Bottling Co. Consolidated Production Facilities Sep 25, 2018 10:00AM
Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis Mar 21, 2018 09:04AM


Feb 12, 2018 08:12AM Sun Pharma Announces Twelve Tildrakizumab Abstracts to be Presented at American Academy of Dermatology 2018 Annual Meeting
Jul 4, 2017 12:27AM Sun Pharma & Samsung BioLogics announce strategic manufacturing tie-up for Tildrakizumab
May 24, 2017 08:03AM Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
Mar 1, 2017 10:35AM Sun Pharma Announces Data from Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology Meeting
Dec 14, 2016 09:00AM Percipient Networks Adds Always-On Protection to Defend Against Modern Social Engineering and Malware Attacks
Oct 1, 2016 05:05AM Sun Pharma to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab, Achieves Primary End Point in Both Phase-3 Studies in Patients with Moderate-to-Severe Plaque Psoria
Sep 20, 2016 09:00AM OptioLabs Wins 2016 CTIA Emerging Technology Award
Aug 17, 2016 09:00AM OptioLabs Named a Finalist for the 10th Annual CTIA Emerging Technology Awards
Jul 27, 2016 01:59PM Almirall and Sun Pharma enter into a License Agreement for Tildrakizumab in Europe for Psoriasis
Apr 12, 2016 02:00AM Surrey Satellite and BridgeSat to Develop Free-Space Satellite Optical Communications Solution
Mar 16, 2016 03:00AM Allied-Bristol Life Sciences Launches iβeCa Therapeutics from NYU School of Medicine to Develop Novel Cancer Therapeutics Targeting the Wnt Pathway
Oct 6, 2015 02:00AM Allied Minds Vice President John Serafini to Speak at NASA Briefing on the Growing Importance of CubeSats in Exploration and Technology Development
Sep 30, 2015 02:00AM AMD and OptioLabs to Offer More Secure Computing Experience
Aug 27, 2015 02:00AM Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University
Jul 29, 2015 08:00AM Suneva Medical Raises $35.4 Million In Capital For Ongoing Product Commercialization Efforts And Expansion Of Business Development Activities
Jun 22, 2015 02:00AM Allied-Bristol Life Sciences Licenses Intellectual Property from Harvard University